Name : Human IL-17B Protein
Product Source :
Recombinant Human IL-17B Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Gln21-Phe180.[Accession | Q9UHF5]
Molecular Weight :
The protein has a predicted MW of 44.91 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human IL-17B on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human IL-17B is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human IL-17B, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-IL-17B Antibody, hFc Tag with the EC50 of 18.0ng/ml determined by ELISA.
Background :
IL-17A, the prototypic member of the IL-17 family, several experimental findings strongly support the role of the IL-17B/IL-17 receptor B (IL-17RB) pathway in tumorigenesis and resistance to anticancer therapies. IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies.
Synonyms :
IL17B; Interleukin-17B
References & Citations :
(1) Bastid J, Dejou C, Docquier A, Bonnefoy N. The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer. Front Immunol. 2020 Apr 21;11:718. doi: 10.3389/fimmu.2020.00718. PMID: 32373132; PMCID: PMC7186465.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
FOLR2 Protein
NPPB Protein
Popular categories:
MIP-1 beta/CCL4
DNAM-1/CD226